CollPlant Biotechnologies Ltd. (CLGN)
| Market Cap | 127.72M |
| Revenue (ttm) | 6.14M |
| Net Income (ttm) | -5.77M |
| Shares Out | 9.91M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | 13.35 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $13.75 |
| Previous Close | $13.90 |
| Change ($) | -0.15 |
| Change (%) | -1.08% |
| Day's Open | 13.91 |
| Day's Range | 13.55 - 13.83 |
| Day's Volume | 15,776 |
| 52-Week Range | 6.00 - 24.26 |
CollPlant (CLGN) is set to report earnings and revenues, and provide product updates when it releases first-quarter 2021 results.
Is (CLGN) Outperforming Other Medical Stocks This Year?
REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increas...
REHOVOT, Israel, March 26, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and p...
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $12.26 in the latest trading session, marking a -1.84% move from the prior day.
Is (CLGN) Outperforming Other Medical Stocks This Year?
In the latest trading session, CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $13.33, marking a +1.76% move from the previous day.
Are you going to sit around to try and price a bottom or are you going to grab stocks that look obviously cheap today?
REHOVOT, Israel, March 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will p...
REHOVOT, Israel, Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on February 24, 2021 it received a notice fro...
REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders. Dear share...
REHOVOT, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has closed the previously announced registered direct offering for the purchase and sa...
Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-...
REHOVOT, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has entered into definitive agreements with several healthcare-focused and other insti...
REHOVOT, Israel, Feb. 8, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced it has entered into a worldwide exclusive development and commercialization agreement for dermal an...
REHOVOT, Israel, Nov. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of COVID-19...
REHOVOT, Israel, Sept. 16, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.
REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.
REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30, 2020 and ...
Is (CLGN) Outperforming Other Medical Stocks This Year?
Is (CLGN) Outperforming Other Medical Stocks This Year?
CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
REHOVOT, Israel, May 27, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, 2020 and p...
As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.
CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Top Ranked Momentum Stocks to Buy for October 11th
About CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tiss... [Read more...]
| Industry Biotechnology | Founded 2004 |
| CEO Yehiel Tal | Employees 52 |
| Stock Exchange NASDAQ | Ticker Symbol CLGN |
Financial Performance
In 2020, CLGN's revenue was $6.14 million, an increase of 164.75% compared to the previous year's $2.32 million. Losses were -$5.77 million, -48.28% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for CLGN stock is "Buy" and the 12-month stock price forecast is 23.00.